-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 JMtvS9P9OlCV1I01sPPAggcPmVSKy71ytBBVNWSp7yPPsifbYBvTa9bZHGf/NjTl
 OdJfJxZw80Br4OCDeMpOTA==

<SEC-DOCUMENT>0000950123-10-025558.txt : 20100317
<SEC-HEADER>0000950123-10-025558.hdr.sgml : 20100317
<ACCEPTANCE-DATETIME>20100317160254
ACCESSION NUMBER:		0000950123-10-025558
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100317
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100317
DATE AS OF CHANGE:		20100317

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHAMPIONS BIOTECHNOLOGY, INC.
		CENTRAL INDEX KEY:			0000771856
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				521401755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17263
		FILM NUMBER:		10688888

	BUSINESS ADDRESS:	
		STREET 1:		855 N. WOLFE STREET
		STREET 2:		SUITE 619
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21205
		BUSINESS PHONE:		410-369-0365

	MAIL ADDRESS:	
		STREET 1:		855 N. WOLFE STREET
		STREET 2:		SUITE 619
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21205

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS SPORTS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERNATIONAL GROUP INC
		DATE OF NAME CHANGE:	19860319
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c98011e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): March 17, 2010</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>CHAMPIONS BIOTECHNOLOGY, INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>0-17263</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>52-1401755</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Science and Technology Park at Johns Hopkins<BR>855 N. Wolfe Street, Suite 619, Baltimore, MD<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>21205</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(410) 369-0365</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>Inapplicable<BR></B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="center" style="font-size: 10pt"><B>INFORMATION TO BE INCLUDED IN THE REPORT</B>



<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>Item&nbsp;2.02.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>Results of Operations and Financial Condition.</B></DIV></TD>
</TR>

</TABLE>


<P align="justify" style="font-size: 10pt; text-indent: 4%">On March&nbsp;17, 2010, Champions Biotechnology, Inc. (the &#147;<B>Company</B>&#148;) announced its results of operations for its
fiscal quarter ended January&nbsp;31, 2010. A copy of the Company&#146;s press release announcing such results dated March&nbsp;17,
2010 is attached hereto as Exhibit&nbsp;99.1. This Form 8-K and the attached exhibit are furnished to, but not filed with,
the Securities and Exchange Commission (&#147;<B>SEC</B>&#148;) and shall not be deemed to be incorporated by reference into any of the
Company&#146;s filings with the SEC under the Securities Act of 1933.


<P align="justify" style="font-size: 10pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B>


<P align="justify" style="font-size: 10pt"><I>(c)&nbsp;Exhibits</I>


<P align="justify" style="font-size: 10pt">The following exhibits are filed herewith:

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;No.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"></TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release dated March&nbsp;17, 2010</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="justify" style="font-size: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.


<P align="justify" style="font-size: 10pt; margin-left: 46%; font-size: 10pt"><B>CHAMPIONS BIOTECHNOLOGY, INC.</B>
<BR>
(Registrant)


<P align="justify" style="font-size: 10pt">Date: March&nbsp;17, 2010


<P align="justify" style="font-size: 10pt; margin-left: 46%; font-size: 10pt; margin-top: -11pt">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U> /s/ Mark Schonau&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>

<DIV align="justify" style="font-size: 10pt; margin-left: 46%; font-size: 10pt">Mark Schonau<BR>
Chief Financial Officer</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c98011exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">


<P align="right" style="font-size: 10pt"><U><B>Exhibit&nbsp;99.1</B></U>


<P align="left"><IMG src="c98011p9801101.gif" alt="(LOGO)">

<DIV align="right" style="font-size: 10pt; margin-top: -22pt">NEWS
</DIV>



<P align="center" style="font-size: 10pt"><B>Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results</B>



<P align="justify" style="font-size: 10pt; text-indent: 4%"><B>Baltimore, MD March&nbsp;17, 2010 </B>&#151; Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the
development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today
announced its financial results for the third fiscal quarter ended January&nbsp;31, 2010. Full details of Company&#146;s
financial results are available in the Company&#146;s Form 10-Q at <U>www.championsbiotechnology.com</U>.


<P align="justify" style="font-size: 10pt; text-indent: 4%">Total revenues for the third quarter of 2010 were $742,000 as compared to $984,000 in fiscal 2009, a decrease of
$242,000. Revenues from Preclinical eValuation were $417,000 for the 2010 quarter compared to $83,000 in the
corresponding quarter in 2009, an increase of $334,000. This increase is due to growth in both the number of studies
being completed and customers entering into contracts for the Company&#146;s preclinical eValuation services. This increase
was offset by a decrease in the Company&#146;s Personalized Oncology Services revenues which generated revenues of $325,000
in the 2010 third quarter compared to $901,000 in the corresponding quarter a year ago, a decrease of $576,000.
Although we believe that the results of this business were somewhat effected by the severe winter we are seeing
positive trends in our Personalized Oncology business going into the final quarter of our fiscal year.


<P align="justify" style="font-size: 10pt; text-indent: 4%">Costs of Personalized Oncology Services for the third quarter of 2010 totalled $162,000 as compared to $464,000 in
fiscal 2009, a decrease of 65%. This reduction is due to the decrease in Personalized Oncology services provided year-over-year. Gross margins for the 2010 and 2009 fiscal third quarters were 50% and 49%, respectively.


<P align="justify" style="font-size: 10pt; text-indent: 4%">Costs of Preclinical eValuation services for the three months ended January&nbsp;31, 2010 and 2009 were $202,000 and
$206,000, respectively, a decrease of $4,000 or 2%. Gross margins for the 2010 and 2009 fiscal third quarters were 51%
and (148%), respectively. During the third quarter of 2009, the Company realized negative gross margin on preclinical
eValuation service revenues primarily due to a contractually negotiated reduction in payments and additional testing
with one of the Company&#146;s customers.


<P align="justify" style="font-size: 10pt; text-indent: 4%">Research and development (&#147;R&#038;D&#148;) expenses for the third quarter of fiscal 2010 were $566,000 as compared to
$435,000 in the comparable quarter of fiscal 2009, an increase of 30%. This increase is primarily due to licensing
fees and costs of $130,000 incurred in connection with licensing our third oncology drug candidate Bithionol.


<P align="justify" style="font-size: 10pt; text-indent: 4%">General and administrative expenses for the third quarter of 2010 were $596,000 as compared to $463,000 in the
comparable quarter of 2009, an increase of 29%. This increase is primarily due to the development of our corporate
infrastructure to support our effort to grow our Preclinical eValuation services and includes increased salaries and
bonuses, legal, accounting, marketing, and office rent expenses.

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="justify" style="font-size: 10pt; text-indent: 4%">For the third quarter ended January&nbsp;31, 2010, the Company reported a net loss of $784,000 or $0.02 per share
compared to a net loss of $563,000 or $0.02 per share for the corresponding quarter in 2009.


<P align="justify" style="font-size: 10pt; text-indent: 4%">The Company&#146;s cash position on January&nbsp;31, 2010 was $1,479,000 compared to $1,728,000 at April&nbsp;30, 2009.


<P align="justify" style="font-size: 10pt; text-indent: 4%">Recently the Company commenced a private offering to &#147;Accredited Investors&#148; as defined in section 2(15) of the
Securities Act. The Company is seeking to raise up to $10.0&nbsp;million dollars through the private placement of
unregistered shares of its common stock. During the third quarter of 2010 the Company received gross proceeds of
$2,100,000 from the private placement of 2,800,000 shares of the Company&#146;s unregistered stock.


<P align="justify" style="font-size: 10pt; text-indent: 4%">For the nine-month period ended January&nbsp;31, 2010, revenues were $2,993,000 compared to $2,701,000 for the
comparable period last year, an increase of 11%. Total operating expenses which include research and development and
general and administrative, were $4,000,000 compared to $2,235,000 for the comparable period last year, an increase of
79% and the Company reported a net loss of $2,371,000 or $0.07 per share, as compared to a net loss of $855,000 or
$0.03 per share for the comparable period in fiscal 2009.


<P align="justify" style="font-size: 10pt; text-indent: 4%">Dr.&nbsp;David Sidransky, Chairman of the Board of Directors of Champions Biotechnology, Inc., commented, &#147;This past
quarter, although we saw reduced revenues from our Personalized Oncology business, we continued to see solid
performance from our Preclinical eValuation business. Having made strong progress in building the integrity of our
platform for the Preclinical eValuation business, we can now more fully implement our primary objective to in-license a
pipeline of high potential oncology drugs and compounds. The Company progress to date is evidenced by the following:


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The Company&#146;s quarterly Preclinical eValuation revenues increased 402% year over year.</DIV></TD>
</TR>

</TABLE>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Champions entered into an exclusive Option Agreement with a leading Canadian research organization to
review a cancer drug candidate. This brings our total number of products owned, licensed or under option
agreements to four.</DIV></TD>
</TR>

</TABLE>


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Champion&#146;s Preclinical eValuation business expanded and initiated new contracts with several major
Biotechnology and Pharmaceutical companies.</DIV></TD>
</TR>

</TABLE>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Champions has received signed subscription agreements totaling $3.0&nbsp;million to date of which $2.2&nbsp;million
has been received in our private placement to accredited investors.&#148;</DIV></TD>
</TR>

</TABLE>


<P align="justify" style="font-size: 10pt">For more information regarding Champions Biotechnology&#146;s business and recent news, please visit
<U>www.championsbiotechnology.com</U>
<BR>
To learn more about Personalized Cancer Treatment please visit www.personalizedcancertreatment.com.


<P align="justify" style="font-size: 10pt"><B>About Champions Biotechnology, Inc.</B>


<P align="justify" style="font-size: 10pt">Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor
specific data to enhance and accelerate the value of oncology drugs. The Company was co-founded by David Sidransky,
M.D. who with Manny Hidalgo, M.D., Ph.D. developed the Company&#146;s Preclinical Platform; a novel approach based upon the implantation of primary human tumors in
immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts&#153;) in a manner that
preserves the biological characteristics of the original human tumor. Early studies suggest that these Tumorgrafts
closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients.

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">4
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<P align="justify" style="font-size: 10pt">Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of
novel therapeutic candidates through pre-clinical trials. As drugs progress through this early stage of development,
the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate.
The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized
patient care and to Companies for evaluation of oncology drugs in models that integrate prognostic testing with
biomarker discovery.


<P align="justify" style="font-size: 10pt">Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation
of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally.


<P align="justify" style="font-size: 10pt"><I>This press release contains &#147;forward-looking statements&#148; (within the meaning of the Private Securities Litigation Act
of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally uses words such as
&#147;believe,&#148; &#147;may,&#148; &#147;could,&#148; &#147;will,&#148; &#147;intend,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;plan,&#148; and similar expressions to identify
forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company&#146;s
actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen
factors. See Champions Biotechnology&#146;s </I><I>Form 10-K</I><I> for the fiscal year ended April&nbsp;30, 2009 for a discussion of such
risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking
statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions
Biotechnology&#146;s future results, levels of activity, performance or achievements may not meet these expectations. The
Company does not intend to update any of the forward-looking statements after the date of this press release to conform
these statements to actual results or to changes in Champions Biotechnology&#146;s expectations, except as required by law.</I>


<P align="justify" style="font-size: 10pt">CONTACT:


<DIV align="justify" style="font-size: 10pt; margin-left: 1%">The Investor Relations Group, Inc.<BR>
James Carbonara<BR>
&#043;1-212-825-3210
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">5




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c98011p9801101.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c98011p9801101.gif
M1TE&.#EA_0!%`/<```!KO0!SO0!SQ@![Q@![S@"$Q@"$S@A[Q@B$Q@B$SA"$
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M[[6UA+6]>[7.[[76[[7>[[V4`+V<`+VE`+W.[[W6[[W>[[W>]\:<`,:E`,:E
M",:E$,:E&,:E(<:M",:M$,:M&,:M(<:]6L;6[\;6]\;>[\;>]\;G]\ZE&,ZM
M$,ZM&,ZM(<ZM*<ZM,<ZM.<ZU(<ZU*<ZU,<ZU.<ZU0LZ].<[.K<[>[\[>]\[G
M]\[G_]:M*=:U,=:U.=:U0M:U2M:U4M:],=:].=:]0M:]2M:]4M:]6M:]8];&
M2M;&4M;&6M;>]];G]];O]]Z]8][&4M[&6M[&8][&:][&<][&>][.8][.:][.
M<][.>][.A-[6>][G]][O]][O_^?&8^?&:^?&<^?.>^?.A.?.C.?6>^?6A.?6
MC.?6E.?6G.?6I>?>E.?>G.?>I>?>K>?O]^?O_^?W_^_.A._6E._6G._6I>_>
MG._>I>_>K>_>M>_>O>_GK>_GM>_GO>_GQN_OUN_OY^_O_^_W[^_W__?GK??G
MM??GO??GQO?OQO?OSO?OUO?OWO?WUO?WWO?WY_?W[_?W]_?W__?____WWO_W
MY__W[___[___]____P``````````````````````````````````````````
M`````````````````````"'Y!```````+`````#]`$4`AP!KO0!SO0!SQ@![
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MYZ7.[Z76[ZVM:ZW&YZW&[ZW.[ZW6[[6UA+6]>[7.[[76[[7>[[V4`+V<`+VE
M`+W.[[W6[[W>[[W>]\:<`,:E`,:E",:E$,:E&,:E(<:M",:M$,:M&,:M(<:]
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MWO?WY_?W[_?W]_?W__?____WWO_WY__W[___[___]____P``````````````
M``````````````````````````````````````````````````C^`-\)'$BP
MH,&#"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3#&F](=/E
MC3&4,&/*G"F2EA$,"`8$T(D@1!>:0(,*'6JPRX,``03L7+H3!3*B4*-*!4E&
M9X`".W7JQ!H`P\NI8,.*;4@K0M:K6L_J9#&VK=NV4Y2FU3KW*JFW>/,.1:%V
MZ]P!.I?H'4SX9#H)2P$G5HMT1^''D#UJ@R#WZMD"?I/*B,RY<\7#=!G7=>RY
MM&F&)!AC5<PZ`);3L&,31/*W+]H#D63K/AWIP.6EJY=2V$T\;[IS[]"E>W=<
M8+H1BUG/U>&NN'6IZ92?0Z>\>_?L[[K^U)8^@("62K'"75\/%-TY;>B,9=_>
M?;NV]\:.UDT;`,(>.7/D\<DTU;%G($GI&(/.??`IJ(V"QACSX(+HO/,"8!AF
MB.$)E>AAAQUUZ+$',.8<:*)'Z!QC##81LBCABBO"5]`7!=1HXXT%$(##)!\6
M\N&'C,12SHE$7O2@,2HB&6&2"BYG4"D/()"``@A0224"4BK1"R.&V&'(EU_:
M$62)19;Y$#JS&)/FFFK.,@LV3AZ$C@8/0/!`!'?>B6<#@K%##2M<&G+(H(<8
M@@DQV9BI:$+IN.GHHVYJLU`Z(4@@@0679IKI"G&2LPLFAS`2*J&?5+/HJ009
M0\JJLZSJ*BG^7RG$!0@?T%KKK;9:8$5!GHJ*"2._,L)(,&2B:B8ZD(SRB++,
M*CO+0K188<(')IP@@K765BN"MD4\$N<[X:PB+";D"ON).,:::0PDCSS"[KOM
M'H,0.G]`X8(**:3@0@HOZ.OOO_NJ4(0;L;KSC"?D(NS))9]$DVZ1[/(!B1\3
M2TQQA05IPT41+G3<L0X=W_#QR"Z`[/$+/H019SBJ8.+)RS`_<Q%X#Q>4W;<C
MX;P0.GST[///CQCD!Q$OD.R#T1T?[8+2)HOL0K<#K1.+)Y]47;4GP4B43A<T
M:$"!!!J8,`4M!9%20PTT&'&0%S2@G89",8Q``@IW(83,#F?7\`;^0K3@C?;>
M`O6=]^`\8%$W0;3DC41"I"R!`@828#`"$'\@E`X09^\0*T%OQ%"##E\81$H1
M)&`@>0U=2+J0,6ZT[D;/K[O1!B0%/9*#"T3XH/ONO/?N>^\W^$"V0.[L4K4J
MGR#_B<P/D8&!4DDAA90"1F#\#AE(`0"!SB@`$```0"3TAO0`U"`^^1!L/A`+
MWG\?OD"12(\4]-XC$,/FXP,`P`/JOV-,#0J0'O2:<KB!H`,!W@,`6PP"!/T!
MX`4%64(`HR>]""Q!=0B9Q1G:(+LVA,&#L@O:0(R1!"(0H0A$0,()5ZA"%:+0
MA2Q,80Q]4(4X%>\3J\"A#J'AD")8Q2K^E4$*![Z"!JU@P'KK6\H1$L(7K31@
M>`;IS5E(0Y`BGD5M`B&%;ZR"%/Y0`(IO.(!.*(#$=T2"`EV,7A`;0(:"(`,"
MK!%,08ZP%/,-9`E,F5]:()B01YSA@V%P7>O"P`>"N`$)B$PD(IV@2"0P4I&/
M3&0D'8D$V@V$';!8A28WN0I3+02/E1D`!!J`@*3H)`+#P]X8=<8"I0B@"`@A
M!0($P)HH($2*=`&<0-"!QK3(T8RE!,P!AOE#I)!@(&_0"@60,Q!:'&4I`E#`
M*$VY%%TFIP%I08`?"F*$.C93`:X\@.DFJ)30)00280C#']/)SD#&B0M(J`(2
MMA#/>=:3GO+^Q*<]\WG/?H:A(.%@Q2I805""QF(="O'#7'80"?A$H@@-"$`#
M<B,0*P[@B`9IP5*PR$"FZ`0#"/%#,*W"@3@!@3'O>P<IEJ*`-/@A$F_HPO.T
M`KADCA&)'SB+!LA`BW0@@PPYU0HJ!X(,LZ1%`E!\1S=U8L=W8$$N$,A-@J9@
M@0#08"&/X$(ZM=K.='[%&/RDIUCM.=:RDO6L8^6"^I[!"E@05!<$S5I"H+.3
M`_RD(*48`1H(HLH`#,<@+%#B02:C$P5$0"YOB^(6SV)+8"9&)QR-1"D#\``D
MT@(QD!6(0G<B`68Z-2TL*.,[:,"4E*(CHJU!`4'HR-2!G+2U!-'^!A8P&-(M
M<($+6\AM%6R[!2N(D!2VO:UPATO<XAJ7N%L0X25CH8M8[((5SF6%)Q6KF)0N
MI(B``:E!8K`46!KDJ4G1`1:6HEK%,D8!+X$.A@2;Q2T^L2`UD)X=X;`4#&`P
M!/6E[4`HM90(J$X;V`S-`%*ZU``TM<`4H"A$'E$%+E3AP;?=PH.K\,]W/"(,
M7#B#5C6LS@U[N,,@YK"(/US(@D##N;%`<2Q(=)`HL/0I#>DK!`#A!S_0N,:I
MT<D2#:*!I0#"&-@,``(*J-DM0@"S`6C!>'72``W(Q;LJ=2^,!T+:`0C`CC;U
M*\9H`4ZD3"$A%AW`-M\Q&:4@``)+.0#^X`K<U"Z<!0$J,-Q#1C'/W3X8"0[>
M+1+(QH>N^OG/@`ZT&PPBCEVD&!@HWL5T"1)?G8S@(59<C6(P,Q<H(U,Q'!!(
ME0/`@R@&$P-AE,MBO=#H`'`4$,%L@&71K!,E""29.UGFJ[5R@%(D!,"*^?(U
M"XL&)$?@)4=P95.U@>3Y(4`#1D@JW^3)['A"H9X4U@8?-MB&:EO[VMC.MK:O
MO<$RN@,8N_C%+L(][F`4B"`J6$H,FA>=I,A%,0*PKD`TJI/7F%&HZHO?&-_Q
MVK,<D[LZ'LA*L=+22+P4"Y@%#$45>E.!8$$K"A`M03"@%3EJ0S\(4(D8C?D.
M)=#2P`3Y`P3^`""`CUM%`;]$B#88Z026NYR2L!.DS&=.\YK+O'_/^`4P=*YS
M<*.K(/0.P`(;8E&EM$]^6I%W*13`Y#CAM]X%Z<V^T8&!LRB`;*W<"92E")RZ
M!("/[Z#O1U57E9V@EU$2D(NKR4P9(=^E"-!<`AYAV\P=H'E^I5T(%U+8R+Z[
MX1$_"[S@!T_XP,NK(-[0^3*`P?B=4\,@.Z@ONPO+@AB\H`4OL+Q1`V#I=\!=
M)P]`@>A1(`&2%D2D2*'`<L9GE<8"/``[CG)6Y!+$$&`0U@/H[*NW.`!K%H3+
M2S'G:7E2MR8*60-:N:I!M(&&'6#`-VFV=4+<L$(4OG"%)D2"LMS^Q7UX0<+[
M[@+_]\-/?G;UKQK!2'\PB*'^8IQ;(%[(2N\=8E'M%N3UL2=SPN671L",&7Y;
M)`%.$GD!$`(#<2%:-Q"/D!-<U#X"``%&\"U91D8"@6L[`78&,7="-CP7MQ-#
M)A!%U6Y-=4LQ4$L*00NZDSLJZ`,F9$*Z@P2/0`K+TB[;URXV6(,T:(,ZN(/N
M<G[.$`S/0`S,0`S.((1#0A#(@%H!H`$Z\PYOD%1]]5<%D76OQ%=,`3VN=!9#
M]PZHEWM.H@T1<`"'\WJ1-5D(4`,_``0_L`1HH%]A)QS6\P)IEEAX%6`!\&@5
MV'8(H&!^<`"A!'(#H0V^)Q#&QU$(`07^*9B(P;,[N<,%HR"#JQ*#CSB)D$B)
MDD@*E)B)I``)_>,-Q/`,Q0"*HE@,ZE$0/`!-*)!4Z+`$XA0K]:<S*[!1!/%T
M`>``HU0G#3!*$`=%7$>!%=58`O$"T!-[I.!$35@0811KGH5+`Z``=S40?H!D
M`T"'PQ<`"E!`&J@8(X@"`Z`Y!9%C`9!R!^$&2[,T1Z,[.G`#P;,T-\`%D$(*
MCP*/D#*/].@H_4,-T)"/^IB/SU"*L55L#E`#6)`%.X!&J9=*PN%9211P`@$(
M.B$`3Z0-$CF1R$"+'"52@"&`"4&&`X%+[[40$XA$04!!`Q`"1H`%CL,?ZQ:(
M&/=_`I%NB@'^B.D0>4K1`#+0!6CP!2J0%H"P,T>C`S/@`CD`,K>3CB\`,CI0
M!6M""VI""[20)D\9E;,@E50YE5;YE/K5#OL(#=.0CUWICP0!"!'U<?)#2SIQ
M`&-F10*``3H3=%!6:B-($$L6`!+P%;TH<0*!?P*7:FYH$&+G5[25#H%%EF5I
M%2/P+67F=AG#:DEA1\<045<H/8J!APLQ!BY0-)>9F46SF9F)!*1P#DJB)+2@
M(DQ"FA%RFDQRFA%2$.(P#=3PFM,0#:\9#=.P:`01"577?_*#`0H6A:*5;DJQ
M8UPF%PJ6,0ZP%%Z@6:4D`!J)$(/)>1VY%!^I$+#&G`HI$#OPD%[^=V4X8X&X
M81"`L%A-50K<2$UI`0!?U!#:<#N8Z3'NZ9XIH`-A$!^AZ2)*4IHO@@U,J9\/
MPI\$X0[50`T!6@T#*J#4`)89LP2EESV<5013]@YH4%]MN12+\PX:>$P)T6\D
ML!R0$`"^P98;N12_I$4[T0`/BA"P)DY]Z0<G,$'2HP`H0(>Q91;66)P#$056
M$9=HH`*0&3T-4`/],WTFD"_[DB]&>J3Y(@(NL&?<@0W]J0U.B@Q..J4O$A\+
M4J6T@$3EX`W>0`W@T*5?ZJ74\',)@0Y^@`5&L`18\`<ZHPV18'#2]WN```EO
M`&.E\`<O%:2!^*8OY1QO^@9Q>A"T\*?^&)0.?&JCEO.G@6H0M8`&2Y"F/*40
M;_JFQ_BF/W80R/`&61`%6)`&)]H0/R`"*6`"HGH"^6*J1HJJUN("76`,YY`=
M\*$-US"KU^`@$ODB$U*EU@.@X%`-X."EOAJLX$`.-7,=QC`MUR("(O`!RJJL
MS+JLSKJL+Q`%D""K!`H-S[!SNU`,U\`=WLH=\/&M`Q$.O=JKX2"LP5HLQ4H<
M;P`"&F`K\/H!N'(KM7(!'_`$LMF502ANJX`\Q9`=W\$=`.LDX@`.Y!H.!WNP
M!AL.[;"NUQ$%%J`!$BNQ&#"Q%BNQ%Y`!-N`(KOF:7!D,B,8*G_`K_YH<[F&R
MS>$.Y("P+-O^LBYK$-0P#3+KFL1*/*Y9$.`@#+Y`##7[#M4@LUPYLP1"#M(@
MM%RY:.1`#+X@#-/ULT<H$./P#,0:#M/PM`(1LXDR$.`P##O;L^^P#M,`#@D1
M#EP[#&3ZG]/@"[Y0#`U+#L_P>`51#=*P:.[@FM7QLP5A#G-+$-E`#6H[#>HJ
M$3\0`9>"`19@N!1PN!:0N)B"`4T`#,PP#<\`#02:K<PELI]P"8?P"TZR'!B#
M#NQ`#N(0#N(@NJ1KNJ([N@A5$)6P!J[KNG/P"M41#FPP"&2R#I[`!FN@!FM`
M![(@$(KPNFP0!Z\;#K'PNLA+"-7A#K!`!ZZK!FP0"NC""6L@#03^\0EL\`OO
M\`IKP`CGU@Z$<`<_5PZB(`>[NP9X``L%0@QK(`H'P0Z?,`?G&[OO]PR)\+QK
M4`C#4`UX$`?#0!#A@`=LP#P"00YRD`<(=;^Q0!#/P`:;,!#3$+QJP+N(0`R?
ML0,.0+@:+`$;S,$10`6[X`R,!PW=4`S@UG._`%>?P`AV\`DEX@XEP@[F(`ZC
M&P[K4,,WC+`YK`[B\'[OX`Z*P`:<(`JHP`FZVPOO(`X'7!WE$+QXD`JP8,1K
MX`KO(`N=$`J*<,"AT`FBL`Z]L`:(L,5B_`H"(0IK(`>=``NH@`=JH`?M0+W6
M.Q"IL`;:^PK$2\4"80YZ,`?$:@[!2P?^GR`+G$"\J2`0TK`&H6`0[M`(:W`'
MH@`+H4"\G5`@SV"^B_`*KQ"\<U`.PK`&@T"FF[`&G\`K<X`'Y@#$<2`'</L.
MT[`&#\S*<Z`&BH#)P;L&!*PU`/0`=](`>&(G>/(`0Y`,O^!<Q!"RNS"YM`FR
MN[`*OT('HE`.Y;`.Y##-TEP.Y%#-UTP.UKS-VJS(BR`'TP4,<=`([T`.<Z`'
MU>$*:Z`(_O@,<Q`'%BP0#=P)!'&\N7`0SH"^TS"NFX#$<$P0JK`&PO`.L#"\
M<A#/X(L'Z!+0BC`.`R$-\NL,[_`,:X`*!J$+:T`(TS4->"#0[U`.@[`&LDL\
MO0`,`D&]B?S^#KX`QNQ0$.5PP.P`Q*Y+"#7;RISP#NR`"%-<(,R["5X[$4%@
M)0S```TPU%12`JN@"Y_`"L^UU+]`#%[:J]60<P+%PG-`#.RP#M$,S5K=U5OM
MU5H=T]X,S@,Q#&MPT^(0(.Y0#G,P!]]0$++@R@^-R`3QQ0ML$(RP!KZ`$$:\
MRN^@SMH+"W&`"&Q`!V++#GJ`!]>,!W/@U^]PO`]\R.Y+$.V@!VNPSP3Q"^O\
M#IU,S@A!#AWM#.9\V09ASGD0TXHP!X7@RM4!#4+\#NRK"#ZL$5GP``.`);@]
M)66`"R_#"I[`")^P"\``#>`@#M;\JXCV"9Y@"&L`"N9@#NR0U>S^4`XRO`[0
M3=WF8-W3';H'X0[?'`J8[`F,_7CC$""LS`:*8!#A$"`M_0[%$`<I+1#'2PFO
MX`HY]`K0/`A\S-=QP`GUC<GW.]"PL`:QP+V*<`[NH`=T4`[4L-FD;,H4;=$$
M00UR@`@^7`YX0`?D,,=[_0Y;2PS#,`QB^P[-X,G!B\<N'2#E`,1S,`WW"PNL
MW-]_O0:Z$!*1T`&`82,&X`&WL,*_;0>=L`JQ$`P'VM+L$`[40`S+C`G,/<7A
M`,/N$-WM(.54S@Y3'MT(X=WFR[NNBP?[G-:#`-MG;1`8/@=DX@QL0,\#\<7/
M.\%K\`VFW=X&(<43[.9R$-AZ+=.HX`[^A(`'Y8#F-UT0[)#AY2#9!3$-<;`(
M!M$.A0#.H;`&$OT.GX"\9"P0C[X&B2#G!!'G0,P&XD`-<\`&TD`-KVW&_QL2
MZ7`$#$!+-=(#N"`JAT`'A8`)P0T,7EH.[5`.2,X,L<#,AD`'<L`(GD`.SPW#
MIUSLR'[LLTT\B\`&L`#BP_`)<J#8::T',9[>..O)[?W>\?W89QWBS3`,6`W2
M<X"@`V'$J3`,PC`,P*`)'CW@2!P.=.#LB;#@U!`'L@U0<F"[ARSA`_$-;$`(
MFO[1=[#@<XS$[R`-JO`*BR#2`T$.\\Y#!_'2I\WB8JO9@Q`+P3[CE5X3,C!+
M`6`&MO`E=<#^!G;`,+'P"\7@JZ-;#="`:*IP"<S-!J]0X._0#J<,Y3J?\Z><
M$%H.EM0KVFIM#G@@!Y@]$-P;WVC>[5^,\`41RC!.$"O^#H/LUX!-T&N`\-(0
M!VQ0RN0PZ'(@\4A/UQ0]V0,!OFQPZ@.QTN1LUHI.$&;=\>^0"'+PTP_/WNY`
M]]90QFLP!W)PT^^="(%K]QD1"34``3T`!HM@"'+`!G4@[*L@W-!@H-"@Y"++
MPN;;">MP"4/B#I[_^:#_^0JAY:M,#JM=M7.@O-N;T:LL#'*@R@,QS_6\!E%_
MZ&>L]M60")R0#49\RZWP[@0^]M..+@,^"*L\#/+[>/UN$"M-!T?^[PRA+C/K
MD`=3W-[N,.D=S^=L4(KN@.`#P=9Y,"2I78KM$+QQP`@_?+^:+Q#ET`IU<*#]
MV!'(L`1,8`K-#B"&\@G.!;D_"&XBN]P`08?-FD;F0H5[E]"=0H8)'3Y\Z$X1
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M1J:)J)`Y$`('.H3VFF,0<R0ZD*4Y7DH(G)X"W`2<=SZ9C#8/9Q-&%!%36266
M7X!AAI@4@P'F%]-2$5&47Z;IY,,/R0$GG!S#6><A<,:!:)UIGJ$FN(?:"4>V
MD')D4D<EVZ'FF6EZW"N<=AY:!YQLWLD2)"S#,9++::2I)DPDF\RQ'(?6H688
M;ZZT#!QIGEEW$"(<%R)L#G$>"@?(=\@!$Z)Q]N1SSCJS5--&11=U9QUQQ/$2
ML3V\6;122R_%-%---TUHO+,X!354\ZH!IQIJG&EQ%U96H5145U^%-=8/Y92U
H5AO%H=(A=L))TE9??P4V6&$U;2?,88]%-EEE@35V66>?A9;3@```.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
